Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US74587V1070
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG0018YXYX7
PBYI
Puma Biotechnology Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Puma Biotechnology Inc
ISIN
US74587V1070
TICKER
PBYI
MIC
XNAS
REUTERS
PBYI.OQ
BLOOMBERG
PBYI US
Wed, 04.11.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 2, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 18,500 shares of Puma common stock to three new non-executive employees.The awards were granted under Puma’s 2017 Emp...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.10.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, November 5, 2026, following the release of its third quarter 2026 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 1...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.10.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive employee.The award was granted under Puma’s 2017 Employme...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.09.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA®-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer. The ALISCA®-Lung2 trial is a sequential dose escalation...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.09.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 3:30 p.m. ET on Monday, September 14, at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held September 14-16, 2026...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 03.09.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on September 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 33,550 shares of Puma common stock to five new non-executive employees. The awards were granted under Puma’s 2017...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.08.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2026. Unless otherwise stated, all comparisons are for the second quarter 2026 compared to the second quarter 2025. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commerci...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.08.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 3, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 35,375 shares of Puma common stock to five new non-executive employees. The awards were granted under Puma’s 2017 Em...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.07.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, August 6, 2026, following the release of its second quarter 2026 financial results.The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 min...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.07.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma common stock to four new non-executive employees. The awards were granted under Puma’s 2017 Empl...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 03.06.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 7,000 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma’s 2017 Employ...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.05.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 59,750 shares of Puma common stock to six new non-executive employees. The awards were granted under Puma’s 2017 Employ...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quarter 2026 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 min...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma common stock to five new non-executive employees. The awards were granted under Puma’s 2017 Emp...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.02.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. Product revenue, net consists entirely of revenue from...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.02.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.02.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 26, 2026, following the release of its fourth quarter and full year 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please di...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.02.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 3, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 14,750 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma’s 2017 E...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.01.2026       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 6, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 10,500 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma’s 2017...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 22.12.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitabilit...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.12.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma’s 2017 Empl...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.11.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 11,250 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma’s 2017 Em...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.11.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2025. Unless otherwise stated, all comparisons are for the third quarter of 2025 compared to the third quarter of 2024. Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma’s first comm...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.10.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, Nov. 6, 2025, following the release of its third quarter 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 mi...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.10.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 9,375 shares of Puma common stock to one new non-executive employee. The award was granted under Puma’s 2017 Empl...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.09.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that on September 2, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 25,750 shares of Puma common stock to four new non-executive employees. The awards were granted under Puma’s 2017...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.09.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 1:00 p.m. EDT on Monday, September 8, at the H.C. Wainwright 27th Annual Global Investment Conference. The conference will be held Septem...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.07.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, August 7, 2025, following the release of its second quarter 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 02.07.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 7,000 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma’s 2017 Employ...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.06.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 18,250 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma’s 2017 Emp...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.05.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first comme...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Tue, 06.05.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 12,875 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma’s 2017 Employm...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.04.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR Annual Meeting is currently taking place at the McCormick Place in Chicago, Illinois. The poster is entitled, “CT071:...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.04.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 8, 2025, following the release of its first quarter 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minu...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 02.04.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 23,875 shares of Puma common stock to four new non-executive employees. The awards were granted under Puma’s 2017 Empl...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.03.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that clinical data on neratinib will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR Annual Meeting will be held at the McCormick Place in Chicago, Illinois, from April 25–30, 2025. The title of the poster that will be...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.03.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma’s 2017 Employm...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.03.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach. A live w...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.03.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach. A live w...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 27.02.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023. Product revenue, net consists entirely of revenue from...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.02.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 11:10 a.m. ET on Wednesday, March 5, at the TD Cowen 45th Annual Health Care Conference. The conference will be held March 3–5, 2025 at the Boston Marri...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.02.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 27, 2025, following the release of its fourth quarter and full year 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please di...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.02.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 7,250 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma’s 2017 Em...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.01.2025       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 2, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 24,375 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma’s 2017 Em...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.12.2024       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cervical Cancer were updated to include an addition involving neratinib (NERLYNX®). The updated NCCN Practice Guidelines for Cervical Cancer include...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.12.2024       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 2, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma’s 2017 Emp...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Wed, 20.11.2024       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA™-Breast1) Phase II trial (PUMA-ALI-1201; NCT06369285) of alisertib in combination with endocrine therapy for the treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negat...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.11.2024       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2024. Unless otherwise stated, all comparisons are for the third quarter of 2024 compared to the third quarter of 2023. Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma’s first comm...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.11.2024       Puma Biotechnology
US74587V1070

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 4, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 5,625 shares of Puma common stock to one new non-executive employee. The award was granted under Puma’s 2017 Empl...
Read more
Puma Biotechnology
Technical Analysis Termsheets Terminal
Permalink